1. Home
  2. BDTX vs MTN Comparison

BDTX vs MTN Comparison

Compare BDTX & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

SELL

Current Price

$1.93

Market Cap

171.9M

Sector

Health Care

ML Signal

SELL

Logo Vail Resorts Inc.

MTN

Vail Resorts Inc.

BUY

Current Price

$140.94

Market Cap

5.2B

ML Signal

BUY

Company Overview

Basic Information
Metric
BDTX
MTN
Founded
2014
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Services-Misc. Amusement & Recreation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
5.2B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
BDTX
MTN
Price
$1.93
$140.94
Analyst Decision
Buy
Hold
Analyst Count
8
13
Target Price
$10.00
★ $143.85
AVG Volume (30 Days)
533.3K
★ 1.0M
Earning Date
11-05-2026
09-28-2026
Dividend Yield
N/A
★ 6.29%
EPS Growth
★ 130.71
N/A
EPS
N/A
★ 4.12
Revenue
N/A
★ $2,838,204,000.00
Revenue This Year
N/A
$6.65
Revenue Next Year
N/A
$3.51
P/E Ratio
★ N/A
$33.74
Revenue Growth
★ N/A
N/A
52 Week Low
$1.60
$118.51
52 Week High
$4.94
$163.34

Technical Indicators

Market Signals
Indicator
BDTX
MTN
Relative Strength Index (RSI) 47.02 51.22
Support Level $1.61 $126.76
Resistance Level $2.31 $145.77
Average True Range (ATR) 0.08 4.49
MACD -0.01 0.50
Stochastic Oscillator 57.14 68.45

Price Performance

Historical Comparison
BDTX
MTN

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About MTN Vail Resorts Inc.

Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.

Share on Social Networks: